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Background: CNS axon regeneration inhibitors such as Nogo and CSPGs (Chondroitin Sulfate Proteoglycans) are
major extrinsic factors limiting outgrowth of severed nerve fibers. However, knowledge on intracellular signaling
cascades and gene expression programs activated by these inhibitors in neurons is sparse. Herein we studied
intracellular signaling cascades activated by total myelin, Nogo and CSPGs in primary mouse CNS neurons.
Results: Total myelin, Nogo and CSPGs stimulated gene expression activity of the serum response factor (SRF), a
central gene regulator of immediate early (IEG) and actin cytoskeletal gene transcription. As demonstrated by
pharmacological interference, SRF-mediated IEG activation by myelin, Nogo or CSPGs depended on MAP kinase,
to a lesser extent on Rho-GTPase but not on PKA signaling. Stimulation of neurons with all three axon growth
inhibitors activated the MAP kinase ERK. In addition to ERK activation, myelin activated the IEG c-Fos, an important
checkpoint of neuronal survival vs. apoptosis. Employing Srf deficient neurons revealed that myelin-induced IEG
activation requires SRF. This suggests an SRF function in mediating neuronal signaling evoked by axon regeneration
associated inhibitors. Besides being a signaling target of axon growth inhibitors, we show that constitutively-active
SRF-VP16 can be employed to circumvent neurite growth inhibition imposed by myelin, Nogo and CSPGs.
Conclusion: In sum, our data demonstrate that axon regeneration inhibitors such as Nogo trigger gene expression
programs including an SRF-dependent IEG response via MAP kinases and Rho-GTPases.
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Upon CNS injury, myelin- and astrocyte-associated
inhibitors limit re-growth of lesioned nerve fibers [1].
Myelin-associated inhibitors such as Nogo signal through
the Nogo receptor complex (NgR) or PIR-B (paired
immunoglobulin-like receptor B) expressed on CNS neu-
rons [2]. Astrocyte-derived CSPGs activate the transmem-
brane protein tyrosine phosphatase receptor, RPTPσ, as
well as NgRs to prevent axon growth [2]. Once activated,
the intracellular signaling pathways employed by these
receptors are not well understood. So far, Rho-GTPase* Correspondence: bernd.knoell@uni-ulm.de
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unless otherwise stated.and Rho kinase (ROCK) as well as PKC signaling are
known to be recruited by NgR receptors [3]. Further
downstream LIM kinase-cofilin signaling is connecting
NgR with the actin cytoskeleton thereby contributing
to axon stalling [4].
Notably many other signaling pathways including cAMP/
PKA, PTEN/AKT, mTOR, GSK3β and MAP kinase sig-
naling have been implicated in axon regeneration [3]. For
instance, elevating neuronal cAMP levels emerges as
potent mechanism to bypass axon injury [5]. In addition,
MAP kinases such as p38, ERK and JNK are involved
in CNS axon regeneration [6-8]. ERK is involved in
peripheral [9-11] and central [12-14] axon regeneration.
However it has not been investigated in much detail
whether these signaling cascades are activated upon NgR,
RPTPσ or PIR-B engagement by their ligands. In this
study we analyzed whether Rho-GTPase, cAMP/PKA
and MAP kinase signaling are mediating signaling uponral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Axon regeneration inhibitors enhance SRF mediated
gene activity. (A) Reportergene assays were performed using a c-Fos
derived construct containing a TCF and SRF (“TS”), TCF (“Tm”) or SRF
binding site (“mS”). (B) Myelin, Nogo and CSPGs enhance TCF-SRF gene
activity as revealed by the “TS” reportergene construct. (C) Mutating the
TCF or SRF binding sites abolished induction upon a 2 h stimulation
with either axon regeneration inhibitor. (D) The signaling cascade
underlying myelin, Nogo and CSPG mediated TCF-SRF promoter activity
involves MAP kinases and to some extent Rho-GTPases. MAP kinase
signaling was blocked by PD-98059. Rho-GTPase signaling was inhibited
via application of ToxB (all Rho-GTPases), C3 (RhoA only), or Y-27632
(targeting ROCK). PKA signaling, interfered with by Rp-cAMPS incubation,
was dispensable for signaling to SRF. Numbers in bars indicate
independent cell cultures analyzed.
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myelin, purified Nogo and CSPGs.
In addition, we investigated whether these axon re-
generation inhibitors modulate gene expression. So far,
activation of NgRs, PIR-B or RPTPs has not been con-
nected to modulation of gene expression. We focused
on SRF (serum response factor), a gene regulator mediat-
ing an immediate early gene (IEG) response of e.g. c-Fos
[15], a hallmark of neuronal activation as well as regu-
latory switch of neuronal apoptosis vs. survival [16].
SRF cooperates with TCFs (ternary complex factors)
such as Elk-1 to convey IEG induction. Besides IEGs,
SRF regulates actin cytoskeletal gene abundance [17].
SRF has not been studied in CNS axonal regeneration
so far. In PNS axon regeneration, using facial nerve
regeneration as model system, we demonstrated a
stimulatory SRF function in motoneuron survival [18]
and axonal regeneration [19] involving a cytoplasmic
SRF localization [19].
Here we show that stimulation of CNS neurons with
total myelin, Nogo or CSPGs activated SRF-dependent
c-Fos reportergene activity. Pharmacological inhibition of
MAP kinase, and to la lesser extent Rho-GTPase/ROCK,
but not cAMP/PKA signaling prevented SRF gene activity
induced by all three inhibitors. MAP kinases (i.e. ERK)
were activated upon incubation of neurons with myelin,
Nogo or CSPGs. Further downstream of ERK we observed
c-Fos induction by myelin, a process blocked by SRF
ablation. Finally, we show that SRF is not only a signal-
ing target of axon regeneration inhibitors. Employing
constitutively-active SRF-VP16 circumvented neurite
growth impaired by myelin, Nogo and CSPGs. This
provides first in vitro data unraveling an SRF potential
in CNS axon regeneration.
Results
Axon regeneration inhibitors activate SRF-dependent
gene activity
We employed SRF dependent reportergene assays to study
whether total myelin, Nogo or CSPG modulate SRF activ-
ity in primary cerebellar neurons (Figure 1). For this, the
c-fos promoter was connected to a luciferase-based repor-
tergene construct (Figure 1A). The c-fos promoter (“TS”)
harbors a TCF binding site (“T”) and a serum response
element, SRE (“S”; Figure 1A). Neurons were stimulated
for various time-points (2-8 h) with these regeneration
inhibitors or with the known SRF stimulus BDNF [20,21].
All three axon regeneration inhibitors enhanced SRF
gene activity of the c-fos reportergene containing both
SRF and TCF binding sites (“TS”) with shortest stimu-
lation periods (2 and 4 h) being most effective (Figure 1B).
Of note, all three inhibitors activated SRF to a comparable
level as achieved with BDNF (Figure 1B). Overall SRF
expression levels or nuclear SRF localization was not
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shown).
Next, we assessed whether SRF alone is sufficient to
activate the c-fos promoter or whether SRF requires TCF
cofactors (Figure 1C). For this, constructs lacking either
the TCF (mS; “m” for mutated) or SRF (Tm) binding site
were employed (see Figure 1A). Mutation of either the
TCF or the SRF binding site abolished reportergene activ-
ity upon 2 h stimulation (Figure 1C). This suggests that
myelin, Nogo or CSPG induced gene activity requires
SRF-TCF interaction.
In order to single out pathways connecting myelin,
Nogo or CSPG signaling with SRF gene regulation,
pharmacological interference was employed (Figure 1D).
Interference with cAMP/PKA signaling was achieved by
pre-incubating neurons with Rp-cAMPS. We applied
ToxB to block all three major Rho-GTPases (RhoA, Rac
and Cdc42) or C3 to specifically target RhoA only. In
addition, the RhoA effector ROCK was inhibited via
Y-27632 bath application. Inhibition of MAP kinase
signaling was accomplished by PD-98059, affecting
MEK activation. Results obtained demonstrate a simi-
lar dependence of all three inhibitors on the inspected
signaling pathways (Figure 1D). In the presence of
Rp-cAMPS, all three inhibitors still induced SRF
reportergene activity indicating that cAMP/PKA sig-
naling is dispensable for SRF activation (Figure 1D).
In contrast, interfering with Rho-GTPase signaling
reduced, although not completely prevented, all three
inhibitors from activating SRF (Figure 1D). Interest-
ingly, abolishing MAP kinase signal propagation com-
pletely prevented all three inhibitors from stimulating
SRF (Figure 1D). This suggests that upon activation by
myelin, Nogo or CSPG, receptors recruit the MAP
kinase pathway to connect surface activation with nuclear
SRF signaling.
Myelin, Nogo or CSPG activate MAP kinases in primary
CNS neurons
Data obtained above suggest that axon regeneration
inhibitors recruit MAP kinases to connect receptor
activation at the neuronal surface with SRF gene regu-
lation. To corroborate this, we assessed whether appli-
cation of these inhibitors to primary neurons results in
activation of the MAP kinase ERK (Figure 2). For this,
cerebellar neurons were stimulated with myelin, Nogo
or CSPGs followed by Western Blotting for activated, i.e.
phosphorylated ERK (P-ERK).
Indeed, all three inhibitors up-regulated P-ERK with
earlier stimulation time-points (10 mins - 2 h) being
more effective than later time-points (4-16 h; Figure 2A-C).
This suggests that upon activation of their cognate recep-
tors myelin, Nogo and CSPGs transiently activate a MAP
kinase signaling cascade in neurons.MAP kinases and Rho-GTPase signaling is intercon-
nected at multiple levels. Hence, we investigated a po-
tential crosstalk of Rho-GTPases and MAP kinases
upon axon regeneration inhibitor signaling (Figure 2D,E).
Expectedly, MEK inhibition (via PD98059) reduced P-ERK
levels (Figure 2D,E). In addition, blockage of all three
major Rho-GTPases via ToxB but not cAMP/PKA signal-
ing also reduced Nogo (Figure 2D) and myelin (Figure 2E)
induced ERK activation. This suggests that MAP kinase
signaling induced by axon regeneration inhibitors requires
Rho-GTPases to achieve full activation.
Myelin evokes an SRF dependent IEG response
Activated ERK kinase stimulates gene regulators thereby
inducing a first gene expression wave. Rapid but transient
IEG induction is such a first molecular response initiated
in neurons upon e.g. injury [16]. We asked whether
confrontation of neurons with myelin also stimulates a
neuronal IEG response. For this, cerebellar neurons
were incubated for various time-points (10 mins -
16 h) with myelin followed by quantification of c-Fos
protein abundance (Figure 3). C-Fos protein is absent
in unstimulated neurons (Figure 3A). However, myelin
strongly induced c-Fos at 1 and 2 h of application,
whereas at later time-points c-Fos was not detectable
(Figure 3A).
C-Fos is an SRF target gene (see Background), thus
myelin might engage SRF to induce c-Fos. Indeed, c-Fos
induction is reduced in Srf mutant neurons (Figure 3B).
As c-Fos induction is not completely abolished, other
gene regulators in addition to SRF might contribute to
myelin-evoked IEG induction. To decipher upstream sig-
naling events involved in myelin-induced IEG induction
we interfered with Rho-GTPase (Tox B) and MAP kin-
ase (PD98059) signaling (Figure 3C). Pre-incubation with
either signaling inhibitor abolished myelin-induced c-Fos
induction suggesting that both MAP kinase and Rho-
GTPase signaling are required for myelin signaling
(Figure 3C). In contrast cAMP/PKA signaling is dis-
pensable (Figure 3C) in line with our previous results
(Figures 1 and 2).
In summary, myelin triggers a neuronal IEG re-
sponse mediated via Rho-GTPase, MAP kinase and
SRF signaling.
SRF-VP16 expression overcomes neurite growth inhibition
exerted by myelin, Nogo and CSPGs
Results obtained so far (Figures 1, 2 and 3) suggest that
a first response of CNS neurons upon encounter of axon
regeneration inhibitors is a rapid but transient IEG induc-
tion. SRF also governs transcriptional responses allowing
prolonged cellular adaptions upon neuronal stimulation.
The latter involves SRF’s access towards modulating actin
dynamics via directly controlling mRNA abundance of
Figure 2 Axon regeneration inhibitors enhance ERK activity. (A-C) Cerebellar neurons were incubated with CSPGs (A), Nogo (B) or myelin
(C) for indicated time-points followed by Western Blotting for total and activated ERK (P-ERK). All three axon regeneration inhibitors activated ERK
with shorter incubation periods being more effective. Bar diagrams depict P-ERK levels normalized to total ERK levels for individual experiments.
(D,E) Cerebellar neurons were stimulated with Nogo (D) or myelin (E) for 1 h. Cultures were pre-incubated with pharmacological inhibitors for
15 mins. Interference with Rho-GTPase (ToxB) and more pronounced MAP kinase (PD98059) signaling, but not cAMP/PKA signaling (Rp-cAMPS),
blocked Nogo (D) or myelin’s (E) potential to fully activate ERK. Numbers in bars indicate independent cell cultures analyzed.
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[15,17]. SRF participates in various actin-based motility
processes including cell migration, neurite growth, growth
cone motility and axon guidance [15]. Thus we wondered
whether a constitutively-active SRF protein variant, not
subject to endogenous regulatory mechanisms, mightalleviate impaired neuronal motility evoked my myelin,
Nogo and CSPGs. We employed SRF-VP16, a fusion
protein consisting of SRF and the viral VP16 transacti-
vation domain. Off-target effects caused by VP16 were
controlled by SRF-VP16-ΔMADS harboring the VP16
domain, yet lacking DNA binding activity [22,23].
Figure 3 Myelin induces an IEG response of c-Fos involving SRF. Cerebellar neurons were stimulated with total myelin for the indicated
time-points followed by analysis of c-Fos protein abundance. (A) Myelin induces c-Fos after 1 and 2 h of application. At later time-points, c-Fos is
down-regulated as also depicted in the quantification of an individual experiment. (B) In Srf deficient neurons, myelin fails to induce c-Fos to a
similar extent as observed in wild-type neurons. (C) Myelin recruits MAP kinases and Rho-GTPase but not cAMP/PKA signaling to induce c-Fos.
Numbers in bars indicate independent cell cultures analyzed.
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augment neurite growth in a growth-inhibitory environ-
ment mimicking the inhibitory environment encountered
by lesioned axons in vivo (Figure 4). Here, primary
neurons were plated on coverslips coated with total
myelin, Nogo or CSPG. Neurons expressing the control
protein, SRF-VP16-ΔMADS (arrowheads in Figure 4A;
higher magnification Figure 4E) grew on the Nogo control
peptide NogoΔ21 [24]. In contrast, an active fragment
derived from the Nogo protein (NogoΔ20) decreased
neurite outgrowth of cerebellar (Figure 4B,F) but not
hippocampal neurons (data not shown). SRF-VP16
expression overcame this neurite growth inhibition by
NogoΔ20 (Figure 4D,H). SRF-VP16 expressing neu-
rons on the inhibitory Nogo substrate (arrowheads in
Figure 4D,H) almost achieve neurite growth comparable
to the growth permissive control substrate (Figure 4A,E).
In addition to Nogo (Figure 4A-L), we employed total
myelin (Figure 4J,M) and CSPGs (Figure 4K,N). Similar
to Nogo, SRF-VP16 alleviated growth inhibition onneurites exerted by myelin and CSPGs (Figure 4J-N). Cell
survival measured by quantification of active-caspase 3 pro-
tein levels revealed no difference between SRF-VP16-
ΔMADS and SRF-VP16 expressing cells (data not shown).
SRF and actin dynamics are intertwined (see Background).
Hence, we asked whether SRF-VP16 requires actin
treadmilling for overcoming neurite outgrowth inhib-
ition in vitro (Figure 4O). Indeed, interfering with actin
polymerization by LatrunculinB application abolished
SRF-VP16’s capacity to stimulate neurite growth in a
regeneration-inhibitory environment presented by Nogo
(Figure 4O). This suggests that SRF-VP16 modulates
the actin cytoskeleton to enhance axonal regeneration
in vitro.
These experiments revealed that SRF-VP16 enhances
neurite growth blocked by axon regeneration inhibitors.
Thus SRF can alleviate the impact of extrinsic cues
blocking axon regeneration (Figure 4) as well as modu-
late neuron’s intrinsic growth potential as shown before
[22,25,26].
Figure 4 (See legend on next page.)
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Figure 4 SRF-VP16 overcomes myelin- and astrocyte-associated neurite growth inhibition in vitro. Primary neurons were plated on Nogo,
total myelin and CSPGs, followed by staining for expression of SRF via the VP16 domain and tubulin to visualize the entire neuron. (A-H) Primary
cerebellar neurons were grown on either an inactive Nogo peptide (NogoΔ21; A, C, E, G) or the growth-inhibiting peptide NogoΔ20 (B, D, F, H).
Neurons were expressing either the control protein SRFΔMADS-VP16 (A, B, E, F) or SRF-VP16 (C, D, G, H). Neurons were stained for SRF (green) and
tubulin (red). The active Nogo peptide (B, F) reduced neurite growth of SRF-ΔMADS-VP16 expressing neurons compared to the permissive control
substrate NogoΔ21 (A, E). Expression of SRF-VP16 stimulated neurite growth on the inhibitory Nogo substrate (D, H). Arrowheads point at individual
VP16-positive neurons. (E-H) represent higher magnification images of individual neurons with nuclear SRF localization (in green). (I-N) Quantification
of neurite growth on Nogo (I, L), myelin (J, M) and CSPGs (K, N). In (I, J, K) percentage of neurons with neurite growth is plotted for the various
conditions. In (L, M, N) neurite length was quantified by taking only neurons into account with neurites grown longer than 50 μm. In each bar
diagram, the condition reflecting control substrate and SRFΔMADS-VP16 was set to 100%. (O) SRF-VP16 requires actin dynamics to overcome
Nogo-mediated neurite growth inhibition. In the presence of the actin depolymerizing agent Latrunculin B (Lat B), SRF-VP16 failed to elevate
neurite outgrowth inhibited by Nogo. Numbers in bars depict independent cultures analyzed for each condition. Standard error is provided.
Scale-bar (A-D) =100 μm; (E-H) =50 μm.
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In recent years many extrinsic factors posing regener-
ation obstacles to injured CNS axons were identified
[27]. However how these myelin- or astrocyte-associated
molecules transmit their axon growth prohibiting activ-
ity within neurons is not understood in much molecular
depth. So far Rho-GTPases have been the main signaling
intermediate identified in neurons to connect these ex-
trinsic factors with intrinsic signaling programs resulting
in axonal stalling [3].
Here, we employed CNS neurons to analyze which sig-
naling pathways are activated when neurons encounter
the regeneration inhibitors total myelin, Nogo or CSPGs.
We further investigated whether these regeneration inhib-
itors modulate gene expression, an event largely neglected
in CNS compared to PNS axon regeneration. Our data
show that all three regeneration obstacles stimulated
SRF-dependent gene expression (Figure 1). Interestingly,
both, growth-promoting BDNF as well as growth-
inhibiting regeneration inhibitors stimulated SRF, yet
with different temporal patterns (Figure 1A). Axonal
growth inhibitors activated SRF only at shortest but
failed to activate SRF at longer time-points (8 h;
Figure 1A). In contrast, BDNF typically provides sustained
SRF activation ranging from short time-points [28]
to long-term stimulation (Figure 1A). Such prolonged
BDNF-mediated SRF activity and thereby overall cellular
response might eventually enhance neuronal survival. In
opposite to this, axonal growth inhibitors stimulate a rapid
but transient IEG response (Figure 1A). As IEGs are
well-known molecules regulating a cellular switch be-
tween cell death and survival [16], axonal growth inhibi-
tors might recruit IEGs to modulate an initial cellular
response mediating axonal regeneration. Notably, both
BDNF and axonal growth inhibitors employ small Rho
family GTPases as downstream signaling effectors [1,29].
Rho-GTPases are known to activate F-actin polymerization
which in turn will enhance SRF activity [17,30]. Thus, des-
pite different time-scale of operation, pro- and anti-growthsignals might share Rho-GTPase-to-SRF signaling as
common downstream effector.
Axonal growth inhibitors did not modulate SRF activity
through alterations in either SRF’s nuclear abundance nor
nuclear localization (data not shown). Instead, our data
are congruent with models of SRF activation involving
specific cofactor recruitment to stimulate SRF-dependent
gene transcription [15,17]. Using reportergene assays
(Figure 1C), we demonstrate an interaction of SRF with
TCF family transcription factors to convey an axon re-
generation inhibitor mediated IEG response. TCF family
members such as Elk-1 are activated through MAP kinase
phosphorylation [15,17]. In this study, MAP kinases were
identified as critical downstream effectors activated by
myelin, Nogo and CSPGs (Figures 1, 2 and 3). Thus,
besides Rho-GTPases, MAP kinases emerge as a further
signaling pathway activated by myelin- and astrocyte asso-
ciated growth inhibitors. Our data suggest that such MAP
kinase activation might eventually result in TCF phos-
phorylation and TCF-SRF mediated gene transcription.
In this study, we have not addressed which of the
receptors (i.e. NgRs, PIR-B or RPTPs) are engaged by
axon regeneration inhibitors. However, we noted that
oligodendrocyte- (total myelin and Nogo) as well as
astrocyte-derived (i.e. CSPGs) axon growth inhibitors all
shared a similar signaling profile with regard to intermedi-
ates recruited (i.e. MAP kinase, Rho-GTPase, SRF) and
temporal signaling sequence followed (i.e. shorter stimula-
tion time-points were more effective than pro-longed
stimulation). This result suggests that all regeneration in-
hibitors signal through the same receptor molecules, a
finding supporting the current model that all regeneration
inhibitor indeed share the same neuronal receptor [2].
How do these in vitro findings relate to axon injury
in vivo?
Induction of an IEG response is reported in various
brain injuries including spinal cord injury [31]. Rapid but
transient induction of c-Fos is a key event in regulation of
survival vs. elimination of injured neurons [16]. Thus, our
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astrocyte-associated regeneration inhibitors, propagation
of such an IEG response in neurons might also require
MAP kinases and SRF in vivo (Figure 3). In such a sce-
nario, SRF might be an effector fulfilling the detrimental
impact of signaling initiated by axon growth inhibitors.
However, our data also reveal that SRF might be employed
to circumvent the growth inhibitory potential of these
regeneration obstacles. For this constitutively-active
SRF-VP16 was used which unlike wild-type SRF is not
subject to neuron-endogenous regulatory mechanisms.
SRF-VP16 rescued myelin, Nogo or CSPG evoked neur-
ite growth inhibition in primary neurons (Figure 4). The
latter is likely due to SRF’s potential to modulate neur-
onal actin cytoskeletal dynamics [17,22]. For instance,
SRF-VP16 enhances the cellular F-actin content [23]
and the activity of the actin severing factor cofilin [32]
and might thereby allow for neurite growth on inhibitory
substrates. In line with a beneficial SRF role in axonal
regeneration, we demonstrated before an enhanced
motoneuron survival by SRF-VP16 and impaired axon
regeneration in Srf deficient mice in the peripheral ner-
vous system [18,19].
In sum our data show that extrinsic regeneration
barriers activate a neuronal signaling pathway involving
MAP kinases and Rho-GTPases. In addition we show for
the first time that axon growth inhibitors such as Nogo
elicit a neuronal gene expression program mediated by
SRF. Due to its dual access to regulation of IEGs and actin
cytoskeletal dynamics, SRF might be an interesting gene
regulator to analyze in CNS axon regeneration in vivo.
Methods
Cell biology
P3-P6 cerebellar or P1-P3 wild-type or Srf mutant hip-
pocampal neurons were used. Reportergene assays
were performed as described in [33,34]. Before plating,
cerebellar neurons were electroporated with 12.8 μg
luciferase construct (kind gifts of A. Nordheim, Tübingen
University, Germany) and 3.2 μg β galactosidase. Luciferase
values were measured 48 h later and normalized to the β
galactosidase control. Cells were stimulated with 10 ng/ml
BDNF (Peprotech, Hamburg, Germany), 12 μg/ml myelin
[35], 10 μg/ml CSPGs (Millipore) or 63 μg/ml Nogo. The
active peptide NogoΔ20, and the control peptide NogoΔ21,
were kindly provided by Dr. M. Schwab (ETH Zurich,
Switzerland) and purified as described before [24]. Cells
were pre-incubated for 15 minutes with PD-98059
(100 μM, Enzo Life Sciences, Lörrach, Germany), Rp-
cAMPS (50 μM, Sigma), ToxB (50 ng/ml, Sigma), C3-
Transferase (2 μg/ml, Cytoskeleton) or Y-27632 (16 mM,
Sigma).
For neurite growth assays on myelin and CSPGs,
hippocampal, whereas cerebellar neurons were used forNogo experiments. Neurons were grown on PLL-coated
(100 μg/ml) coverslips followed by coating with inhibitory
substances as follows. 4 μg myelin was dried on coverslips
over night using an exicator. Both Nogo peptides were
used at 35 μg/ml in HBSS for 1 h at 37°C. After washing
with HBSS, coverslips were coated with 5 μg/ml laminin.
The CSPGs were applied at 5 μg/ml in PBS overnight at
4°C followed by laminin coating as above. Before plating,
neurons were electroporated using Amaxa mouse neuron
nucleofector solution as recommended by the manufac-
turer (Amaxa, Cologne, Germany). 3 μg of the indicated
plasmids were electroporated. After 24 h to 48 h in the in-
cubator, immuncytochemistry was performed. Latrunculin
B (Sigma) was applied at 0.2 μM for 16 h in the culture
medium.Biochemistry
Protein lysates were prepared as described before [33].
Rabbit anti-active ERK (Cell Signaling; 1:1000), rabbit
anti-ERK (Cell Signaling; 1:1000), rabbit anti c-Fos
(Calbiochem; 1:5000) and mouse anti-GAPDH (Acris;
1:50.000) antibodies were used.Statistics
Numbers of independent experiments or animals are indi-
cated in the results section and figure bars. For cell culture
experiments, at least three independent experiments were
performed. In each experiment at least 30 neurons were
analyzed. Statistical significance was calculated using two
tailed t test with *, **, *** indicating p ≤0.05, 0.01 and
0.001, respectively. Standard deviation (Figures 1 and 4)
or standard error (Figures 2 and 3) is provided if not
mentioned otherwise.
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